drugset / Trial / NCT00082329

G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers

NCT00082329

NaSingle-groupOpen-labelTreatment

Summary

This 12-day study will test whether the combination of G-CSF (granulocyte-colony stimulating factor) and AMD3100 (Mozobil) is more efficient in mobilizing stem cells for collection than the use of G-CSF alone. Traditionally, the growth factor G-CSF has been given to stem cell donors to mobilize, or push, stem cells out of the bone marrow and into the blood circulation for collection for transplantation. Although a sufficient quantity of cells usually can be collected with G-CSF treatment, some donors do not respond well and may require multiple apheresis procedures (see below) to collect enough cells. Studies indicate that G-CSF used together with a drug called AMD3100 may be more effective in mobilizing stem cells for collection than G-CSF alone. The Food and Drug Administration has approved G-CSF for stem cell mobilization. AMD3100 is a new drug that also mobilizes stem cells in large numbers within a few hours. Normal healthy volunteers between 18 and 60 years of age may be eligible for this study.

Timeline

Start
2004-06-18
Primary completion
2012-10-25
Completion
2012-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject AMD3100 Small molecule 240 ug/kg Subcutaneous
Background Granulocyte colony-stimulating factor Protein / enzyme biologic 10 ug/kg Subcutaneous

Indications

No indication recorded.